Lord James O’Shaughnessy, a former UK health minister and leader of a review into the country’s poorly performing commercial clinical trial sector, told attendees of the LifeArc Translational Science Summit on 23 April that a key contributor to the problem was the “performance breakdown of the MHRA,” which he said was “pretty shocking” at the time of the review, 18 months ago.
The UK saw a 44% decline in the number of UK patients recruited to commercial clinical trials between 2017 and 2021, something that prompted the government to commission O’Shaughnessy to conduct a review of the situation last year
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?